In this study, we want to find out if a combination of 3 different study drugs (Cabozantinib, Ipilimumab, and Nivolumab) will affect the progression of Soft Tissue Sarcoma.
Thank you for your interest, but this study is not currently enrolling.
United States (Nationwide)
Mark Woodcock
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Sarcoma (bone and soft tissue))
24-0298
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
